Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
Maqola

Exploring Potential Mechanisms for Epilepsy After <scp>mRNA COVID</scp> ‐19 Vaccination: An Extremely Rare Side‐Effect

Ahmed Faisal MuteeAbdulkareem ShareefAhl Al Bayt University Karbala IraqS. Renuka JyothiDepartment of Biotechnology and Genetics, School of Sciences JAIN (Deemed to Be University) Bangalore Karnataka IndiaRajashree PanigrahiDepartment of Microbiology, IMS and SUM Hospital Siksha ‘O’ Anusandhan (Deemed to Be University) Bhubaneswar Odisha IndiaVikrant AbbotCentre for Promotion of Research Graphic Era Deemed to Be University Dehradun Uttarakhand IndiaAshish Singh ChauhanUttaranchal Institute of Pharmaceutical Sciences, Division of Research and Innovation Uttaranchal University Dehradun Uttarakhand IndiaSurbhi SinghCentre for Research Impact &amp; Outcome Chitkara University Institute of Engineering and Technology, Chitkara University Rajpura Punjab IndiaBobur Bakhodir ugli AbduvoyitovDepartment of Neurosurgery Samarkand State Medical University Samarkand UzbekistanHayder Naji SameerCollage of Pharmacy National University of Science and Technology Nasiriyah IraqAhmed YaseenZainab H. AthabDepartment of Pharmacy Al‐Zahrawi University College Karbala IraqMohaned Adil
ABI

Annotatsiya

The rapid rollout of mRNA-based COVID-19 vaccines, including Pfizer-BioNTech's BNT162b2 and Moderna's mRNA-1273, has been instrumental in curbing the pandemic, demonstrating high efficacy and safety in the general population. However, concerns regarding neurological adverse effects, particularly in individuals with epilepsy (PWE), warrant scrutiny. Clinical data from case reports, multicenter studies, and meta-analyses (encompassing over 3000 PWE) indicate that most tolerate vaccination well, with seizure worsening in approximately 5% of cases, often transient and lower than post-COVID-19 infection rates. Rare severe events, such as status epilepticus, highlight vulnerabilities, though background seizure incidence remains comparable or lower than natural rates. This review examines potential neuroimmune mechanisms linking mRNA vaccination to seizure exacerbation, emphasising immune activation, neuroinflammation, and epileptogenesis. mRNA vaccines utilise lipid nanoparticles (LNPs) to deliver spike protein-encoding mRNA, eliciting robust immune responses. Potential triggers for seizures include cytokine storms (e.g., IL-1β, TNF-α, IL-6), blood-brain barrier (BBB) disruption, molecular mimicry with neuronal antigens, and autoantibody production, which may heighten neuronal hyperexcitability in susceptible individuals. Neurological side effects, including Bell's palsy, transverse myelitis, and herpes zoster reactivation, are more prevalent in mRNA platforms, potentially tied to LNP-induced inflammation or cross-reactive immunity. While evidence supports vaccination benefits outweighing risks for PWE, gaps persist in understanding individual predispositions. Future research should prioritise longitudinal studies, EEG monitoring, and AI-driven approaches for personalised risk assessment, mRNA optimisation, and pharmacovigilance. Integrating multi-omics and computational modelling could enhance vaccine safety, ensuring equitable protection for vulnerable populations.

Hali tarjima qilinmagan

Mavzular

Identifikatorlar

Iqtiboslar va manbalar